Data edition of
Residue An evidence-graded reference for peptide science

Kisspeptin-10 dosage in clinical trials

What dose levels researchers actually tested, quoted from the trial registry and the published reports — so the numbers circulating online can be checked against their source.

Doses in published trials

Table 1. Dose arms of the principal published Kisspeptin-10 trials, as reported in the cited paper.
TrialPopulationDose armsScheduleRef.
Dose-response, healthy menHealthy men0.01–3.0 µg/kg IV bolus; 1.5 or 4 µg/kg/h infusionSingle boluses; infusion up to 22.5 h1
Sex comparisonHealthy men and women, 4–5 per groupUp to 10 nmol/kg IV, 32 nmol/kg SCSingle boluses and IV infusion2
Chronic SC protocol (2026)15 healthy men1.25–10 nmol/kg/h; 150–180 nmol/h8 h acute; continuous 5 days; 8 h daily for 12 days3
Type 2 diabetes with low testosterone5 men with T2DM, 7 controls0.3 µg/kg IV bolus; 4 µg/kg/h infusionBolus; 11-hour infusion4
Figure 1. Dose levels named in ClinicalTrials.gov arm descriptions that mention Kisspeptin-10, counted once per study (3 interventional studies). Includes titration steps and single-dose pharmacology studies; a level appearing often is not evidence that it is effective or safe.

Arms as registered

Verbatim arm text from ClinicalTrials.gov. Only arms naming Kisspeptin-10 and a dose are shown.

  1. NCT03315325 · Phase 3 · Completed · n=15

    Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

    • Adult men — The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
    • Middle age men — The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
    • Advance age men — The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.

  2. NCT03286517 · Phase 3 · Completed · n=30

    Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

    • Tanner Stage I — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
    • Tanner Stage II — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
    • Tanner Stage III — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
    • Tanner Stage IV — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
    • Tanner stage V — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
    • Adult Group — A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.

  3. NCT03771326 · Phase 3 · Completed · n=14

    KP-10 and Insulin Secretion in Men

    • obese men — To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
    • Normal men — To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.

References

Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.

  1. 1 PubMed George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011. PMID 21632807; doi:10.1210/jc.2011-0089.
  2. 2 PubMed Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab 2011. PMID 21976724; doi:10.1210/jc.2011-1408.
  3. 3 PubMed Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026. PMID 42549827; doi:10.1093/ejendo/lvag134.
  4. 4 PubMed George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf) 2013. PMID 23153270; doi:10.1111/cen.12103.

← Kisspeptin-10 monograph · Why we publish trial doses